Bio & Health
·
Designed Phospho-Tau Binder Selectivity
AI-Driven Biological Design & Engineering (Synthetic Biology)
Across 96 designed phospho-Thr217 binders, how far does 100-fold peptide selectivity drop when tested against human brain tau?
THE QUESTION
Can a designed binder discriminate a post-translational-modification state — phospho-tau at a named site versus unmodified tau — with above 100-fold selectivity, and what fraction of 96 designs achieve it? Affinity is no longer the discriminator now that 34 of 39 disordered targets yielded 100 pM-100 nM binders; state and conformer specificity is.
WORK ORDER
Peptide-versus-brain selectivity transfer loss across a 96-design anti-phospho-Thr217 tau binder cohort
BACKGROUND
What this Apodex Lab is
Tau protein in human brain tissue accumulates complex patterns of chemical modifications during neurodegenerative disease. Generative protein design methods now yield binders with affinities between 100 pM and 100 nM against disordered targets, but discriminating specific post-translational modifications remains an open challenge. In diseased tissue, phosphorylation at residues like Thr217 co-occurs with neighbouring phosphorylations, acetylations, and truncations on the same protein molecule. If an engineered binder cannot differentiate modified from unmodified tau within this dense chemical background, it cannot function reliably as an analytical capture reagent.
Accepted evidence for state selectivity rests almost entirely on assays using synthetic peptides of 10 to 20 residues carrying a single phosphate, titrated against an unphosphorylated counterpart. These measurements demonstrate binding to an isolated epitope, but they do not reveal whether selectivity survives when challenged with heterogeneous tau purified from human brain. The field has not measured the selectivity transfer loss across a design cohort on both synthetic and native substrates. When a binder fails on patient-derived material, existing data cannot distinguish between poor binder discrimination and steric masking caused by co-occurring modifications on the target.
The AI-Driven Biological Design & Engineering (Synthetic Biology) Apodex Lab measures this transfer loss across a cohort of 96 designed binders directed at phospho-Thr217 tau. By pairing biolayer interferometry on synthetic 15-residue peptides with quantitative mass spectrometry on sarkosyl-insoluble tau from four post-mortem donors, the protocol determines the distribution of selectivity loss and maps modification occupancy within ±6 residues of the target site. If the cohort median loss exceeds 1.0 log10 unit and correlates with neighbouring marks, binder engineering shifts from peptide affinity optimisation to epitope-availability targets and multiply modified calibrants. If selectivity transfers with minimal loss, leads advance directly using high-throughput peptide assays.
WHY NOW
Why the field is spending on an assumption
Generative protein design now produces 96-member binder panels against disordered targets. However, the accepted benchmark for state selectivity remains a ratio measured against a synthetic peptide carrying a single phosphate. Real human tau carries dozens of co-occurring post-translational modifications alongside phosphorylation, varying with disease stage and tissue handling. The gap between clean-peptide selectivity and performance on patient-derived tau has never been measured across a cohort. Consequently, current programmes cannot distinguish whether capture failures stem from inadequate binder design or from target heterogeneity in human tissue.
WHAT WE’D BUY
What we would ask a laboratory to run
We are not buying the answer. We are buying a measurement with an interval — and the bars it will be compared against.
A paired selectivity screen across 96 designed phospho-Thr217 tau binders. Biolayer interferometry measures dissociation constants on synthetic single-phosphate peptides. Bead pulldowns coupled to isotope-calibrated mass spectrometry measure capture efficiency from sarkosyl-insoluble tau purified from four post-mortem human brains. Bottom-up mass spectrometry maps neighbouring modifications within six residues of Thr217 in captured material. The deliverable is the cohort median transfer loss in log10 units, estimated with a bootstrap 95% interval no wider than ±0.25 log10 units, paired with its correlation against flanking modification occupancy. Surface plasmon resonance on multiply phosphorylated recombinant tau provides a bridging calibration for eight designs.
SCOPE & LIMITS
Because measurements use sarkosyl-insoluble filamentous tau from post-mortem donors, the estimated transfer loss applies specifically to aggregated end-stage brain tau at phospho-Thr217 and does not describe soluble biofluid tau or alternative phosphorylation sites.
WHO EXECUTES
The kind of lab that can run this
A protein-biochemistry CRO or university core with peptide synthesis, surface plasmon resonance or biolayer interferometry, immunoprecipitation-mass-spectrometry PTM mapping, and access to consented post-mortem human brain tau fractions.
EXECUTOR KIND
wet-lab
WAYS IN
FOR PIs, LABS & CROs
Complete tasks no model can.
Paid per task, credited by name — a “Verified by” line for as long as the discovery it settled exists. You choose the work: browse the tasks above, respond to what you can actually run.
CREATE AN APODEX LAB
Have a question of your own?
Give it its own laboratory. Watch it decompose into an executable manifest.
ASK A FOLLOW-UP QUESTION
Push on our assumptions.
Every Apodex Lab lists what it doesn’t know. Good questions compound.
Every Apodex Lab shares the same verified-knowledge ledger. No laboratory works alone.